Albendazole: A Dual-Purpose Drug for Parasitic Infections and Cancer Therapies
A new review published in BIO Integration details the use of Albendazole (ABZ) in treating parasitic infections and its concurrent repurposing for various cancer therapies. The article highlights challenges related to the drug's solubility and explores advancements, including nanomedicine techniques, aimed at enhancing its therapeutic efficacy in both applications.
Publication Overview
The review article, published in BIO Integration, synthesizes existing literature on anthelmintic drugs with documented benefits. It focuses specifically on Albendazole (ABZ) and its evolving applications in medical treatment.
Addressing Parasitic Infections
According to World Health Organization (WHO) reports, parasitic infections significantly impact global health, contributing to over 16 million annual deaths, particularly in developing nations. The review covers common human helminthic infections such as trichomoniasis, giardiasis, cryptosporidiosis, and toxoplasmosis. These are typically managed with a combination of anthelmintics and antibiotics, often achieving synergistic effects.
Parasitic infections contribute to over 16 million annual deaths globally, especially in developing nations.
Solubility Challenges and Enhanced Delivery
Albendazole is identified as a key anthelmintic drug. However, its therapeutic efficacy is significantly limited by low solubility. Classified as a Biopharmaceutics Classification System (BCS) class II drug, ABZ requires enhanced administration methods.
Albendazole, a key anthelmintic drug, faces limitations due to its low solubility, classifying it as a BCS class II drug.
To improve its biopharmaceutical properties and therapeutic effectiveness, the review explores both conventional approaches and novel nanomedicine techniques.
Albendazole's Repurposing for Cancer Therapy
The review also discusses the repositioning of Albendazole for the treatment of various cancers. This includes its application in conditions such as colon cancer, brain tumors, malignant melanoma, and breast cancer.
The repurposing of ABZ for cancer therapy, whether used with or without nanoformulation, occurred concurrently with the development of its nanomedicine applications.